Spotlight On... Sun said to be discussing $2.3B deal for Intas: DealStreetAsia; FDA issues closeout letter for QuVa's recently acquired facility; Coherus signs on KBI to manufacture biosimilar; and more...

Sun Pharmaceutical is reported to be in negotiations to buy Indian rival Intas Pharmaceuticals for as much as $2.3 billion, talks that Intas says are not happening. In an exclusive based on unnamed sources, DealStreetAsia says the two companies are discussing a cash and stock deal that would give Sun entry into biosimilars. Intas is hoping to be the first Indian drugmaker to sell biosimilars in the U.S. with its version of Amgen's ($AMGN) Neulasta. More from FiercePharmaAsia

> Cipla has launched in India its version of Gilead Sciences' ($GILD) hepatitis C combo drug Harvoni. Release (PDF)

> California-based Coherus BioSciences has an agreement for North Carolina-based KBI Biopharma to manufacture Coherus' biosimilar of Amgen's ($AMGN) Neulasta. Release (PDF)

> QuVa Pharma, a compounding pharmaceutical company backed by Bain Capital Private Equity, says that the FDA has issued a close-out letter acknowledging corrective actions it has taken to resolve issues that came up during inspections at the Unique Pharmaceuticals facility in Temple, TX, before QuVa acquired it in October. Release

> Denmark-based ALK-Abello, which is working on immunotherapies for allergy treatments, has agreed to sell its European veterinary business, including production facilities in Sweden, to private equity investor Fidelio Capital for an undisclosed sum. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.